AI assistant
Biohit Oyj — Share Issue/Capital Change 2016
Dec 5, 2016
3304_rns_2016-12-05_66428887-c2aa-49a6-ac02-08344f5efcb6.html
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Disclosure 347372
Biohit Oyj - Company Announcement
Biohit Oyj’s Option Scheme I 2013 – Management Option Arrangement
Biohit Oyj Stock Exchange Release December 5, 2016 at 2:30 pm local time (EET) Biohit Oyj’s Board of Directors has decided on December 5, 2016 to distribute option rights of the option scheme I 2013 as follows: Graham Johnson 30,000 pcs, Panu Hendolin 30,000 pcs, Niklas Nordström 30,000 pcs, Daniela Söderström 30,000 pcs and Ilari Patrakka 30,000 pcs. For the option rights share subscription period commences on January 1, 2017 and ends on May 31, 2019. The persons have accepted the option rights. The complete terms of the option scheme are available on Biohit Oyj website at www.biohithealthcare.com/investors/corporate-governance. Biohit Oyj Board of Directors Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 [email protected] www.biohithealthcare.com Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com